RxDoctor Payments Data

Christopher Lee, MD

Urology · Vineland, NJNPI 1013901693

Payments from drug & device makers

$14,892in general payments, 2019–2025

Across 362 payments — averaging $41.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$6K
  • Boston Scientific$2K
  • Astellas Pharma US Inc$1K
  • Sumitomo Pharma America, Inc.$571
  • Dendreon Pharmaceuticals LLC$474
  • Bayer$431
  • plus $4K from 44 others

What the payments were for

  • Consulting fees$3,00020%
  • Speaking & faculty fees$4733%
  • Travel & lodging$3,15721%
  • Food & beverage$7,22749%
  • Education$1,0167%
  • Gifts$190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,892 in reported general payments places this provider in the 80th percentile of 401 urology providers in New Jersey.

See all urology providers in New Jersey

Medicare billing

Part B allowed, 2024
$1,334,870
Medicare patients
647
Services billed
17,216

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide22$318,812
MyrbetriqMirabegron238$261,971
Alfuzosin Hcl ErAlfuzosin Hcl1,916$58,310
GemtesaVibegron56$57,791
Finasteride1,423$23,221
Testosterone Cypionate154$12,330
Estradiol138$10,913
Solifenacin Succinate142$7,818
Oxybutynin Chloride ErOxybutynin Chloride195$7,406
Testosterone27$7,178
Tamsulosin Hcl246$6,913
Levofloxacin588$4,061
Tolterodine Tartrate ErTolterodine Tartrate28$3,415
Bicalutamide49$1,917
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip40$1,736

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$1,249$580,783260 claims
Sumitomo Pharma America, Inc.Gemtesa$571$57,79156 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 401 urology providers in New Jersey.

Other urology in Vineland

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →